



Dr. Sanjay Kumar

Sr CMO (NFSG)/Joint Director,
RNTCP, Central TB Division



Tel. : 011-23061428
E-mail : mattoos@rntcp.org
sanjayk.mattoo@gov.in

भारत सरकार

Government of India

स्वास्थ्य एवं परिवार कल्याण मंत्रालय
Ministry of Health & Family Welfare

निर्माण भवन, नई दिल्ली-110011

Nirman Bhavan, New Delhi-110011

No. T-18019 / 01 / 2020 (Part2) -TB

Date :
Dated: 25.05.2021

To

State TB Officers,

Sub: Regarding Usage and Supply of Inj. Amikacin for management of MDR TB under NTEP.

Madam / Sir,

This is with reference to the procurement & use of Inj. Amikacin 500mg for the treatment of DRTB patient on shorter MDR TB regimen.

2) Inj. Amikacin was procured first time in the year 2019 as 3,000 patients courses, **for a pilot study and not as Regular programmatic decision**, to observe the benefit of Amikacin over Kanamycin as part of Injectable Shorter MDR Regimen, the pilot was implemented in 82 districts vide DO Letter No. Z-28015/ 27/2012 -TB dated 14 Feb 2020. The study has been completed.

3 a) Programme Division has decided to implement injection-free **all oral shorter regimen under NTEP in phase manner**. So the injectables will be no more part of shorter regimen & in the States in first phase, patients will immediately initiated on all oral shorter regimen.

3 b) While in other States, patients will continue **Kanamycin containing shorter injectable MDR TB regimen**, till information from Centre to start injection free all oral shorter regimen for MDR TB is communicated.

(letter for starting injection-free shorter oral regimen will be communicated separately and then only this regimens to be started)

4) As per the newly revised and approved PMDT guidelines, **Inj. Amikacin** to be used **as replacement drug in longer all oral regimen and it is Group C medicine at 2nd sequence after Delamanid for replacement**.


टीबी हारेगा, देश जीतेगा

In View of point (3) & (4) following is communicated:-

- i. As the use of inj amikacin will be very limited and the quantity needed will be very less, Centre will not procure this drug.
- ii. States are requested to (i) **Not to put any new patient on amikacin** containing shorter regimen, (ii) For ***Pts already at present on Amikacin containing shorter regimen*** & Inj. Amikacin is not available with the states/districts, **switch the patients on kanamycin** instead of amikacin and continue the regimen with rest of the drug, in case pt does not respond to this regimen then change the regimen as per the guidelines.
- iii. The local procurement of Inj. Amikacin 500mg is to be made at state / districts level, **in case of future use Inj. Amikacin as replacement drug in longer all oral regimen** in pursuance of newer PMDT Guidelines.

The expenses towards this procurement may be booked under the "Budget head approved in ROP 2021-22 for Procurement of Drugs. Technical Specifications are enclosed for reference as Annexure B.

This issues with approval of the competent authority.

Yours faithfully,

(Dr. Sanjay Kumar Mattoo)
Joint Director (TB)

Ensl as above (in local ref.)

Copy to: -

1. District TB Officers-
2. NTEP Consultants : CTD & State